MedTrace Logo

An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer

NCT01442155 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2016-07-07

Study results available
· View outcomes & findings →

Summary

This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.

Conditions

Interventions

DRUG

Capecitabine

Administered according to the Summary of Product Characteristics.

BIOLOGICAL

Oxaliplatin

Administered according to the Summary of Product Characteristics.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01442155 on ClinicalTrials.gov